VMI
XLRN

VHCP Management II’s Acceleron Pharma XLRN Stock Holding History

VHCP Management II’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-156,880
Closed -$4.77M – 24
2017
Q2 		$4.77M Hold
156,880
– – 1.9% 10
2017
Q1 		$4.15M Buy
+156,880
New +$4.13M 1.7% 10

Other funds holding XLRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

VHCP Management II's XLRN Position: Q3 2017 in Review

VHCP Management II sold out of Acceleron Pharma (XLRN) in Q3 2017, closing a stake of 156,880 shares — an estimated $4.77M sold.

VHCP Management II first reported a position in XLRN in Q1 2017 and held it in 2 quarters. The position peaked at $4.77M in Q2 2017. 149 funds tracked by Wall St. Rank hold XLRN as of Q3 2017.

  • VHCP Management II reported no remaining Acceleron Pharma position as of Q3 2017 after selling out during the quarter.
  • VHCP Management II sold 156,880 Acceleron Pharma shares in Q3 2017, an estimated $4.77M.
  • VHCP Management II first reported a position in Acceleron Pharma in Q1 2017 and held it in 2 quarters.
  • VHCP Management II's Acceleron Pharma position peaked at $4.77M in Q2 2017.
  • 149 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2017.

Based on VHCP Management II's 13F filing for Q3 2017, filed 13 Nov 2017.